Chromosomal Abnormalities in Selected Hematopoietic Malignancies Detected by Conventional and Molecular Cytogenetics: Diagnostic and Prognostic Significance

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Unknown venue

• Publication date

  Unknown publication date

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1007/978-90-481-3725-1_6
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• International System for Human Cytogenetic Nomenclature

  2020cited by this paper
• CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS Hypodiploidy With Less Than 45 Chromosomes Confers Adverse Risk in Childhood Acute Lymphoblastic Leukemia: A Report From the Children's Cancer Group

  2016cited by this paper
• t(11;16)(q23;p13)

  2011cited by this paper
• Complex genomic alterations and gene expression in acute lymphoblastic leukemia with intrachromosomal amplification of chromosome 21.

  2006cited by this paper
• Analysis of prognostic factors of acute lymphoblastic leukemia in infants: report on CCG 1953 from the Children's Oncology Group.

  2006cited by this paper
• Prospective analysis of TEL/AML1-positive patients treated on Dana-Farber Cancer Institute Consortium Protocol 95-01.

  2006cited by this paper
• Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL.

  2006cited by this paper
• Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia.

  2006cited by this paper
• Near-triploidy and near-tetraploidy in childhood acute lymphoblastic leukemia: association with B-lineage blast cells carrying the ETV6-RUNX1 fusion, T-lineage immunophenotype, and favorable outcome.

  2006cited by this paper
• Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias.

  2006cited by this paper
• Acute lymphoblastic leukemia with 4;11 translocation analyzed by a multi-modal strategy of conventional cytogenetics, FISH, morphology, flow cytometry and molecular genetics, and review of the literature.

  2006cited by this paper
• Clinical management of myelodysplastic syndromes with interstitial deletion of chromosome 5q.

  2006cited by this paper
• Imatinib preceding allogeneic stem cell transplantation in chronic myeloid leukemia.

  2006cited by this paper
• The FIP1L1-PDGFRA T674I mutation can be inhibited by the tyrosine kinase inhibitor AMN107 (nilotinib).

  2006cited by this paper
• Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for risk-adapted therapy.

  2006cited by this paper
• Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion.

  2006cited by this paper
• The JAK2-V617F mutation and essential thrombocythemia features in a subset of patients with refractory anemia with ring sideroblasts (RARS).

  2006cited by this paper
• Biological and Prognostic Significance of Chromosome 5q Deletions in Myeloid Malignancies

  2006cited by this paper
• Identification of novel cytogenetic markers with prognostic significance in a series of 968 patients with primary myelodysplastic syndromes.

  2005cited by this paper
• Efficacy of lenalidomide in myelodysplastic syndromes.

  2005cited by this paper
• FLT3 inhibition selectively kills childhood acute lymphoblastic leukemia cells with high levels of FLT3 expression.

  2005cited by this paper
• A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera

  2005cited by this paper
• Interphase FISH to detect PBX1/E2A fusion resulting from the der(19)t(1;19)(q23;p13.3) or t(1;19)(q23;p13.3) in paediatric patients with acute lymphoblastic leukaemia

  2005cited by this paper
• Cloning and functional characterization of MEF2D/DAZAP1 and DAZAP1/MEF2D fusion proteins created by a variant t(1;19)(q23;p13.3) in acute lymphoblastic leukemia

  2005cited by this paper
• ETV6: a versatile player in leukemogenesis.

  2005cited by this paper
• Arsenic trioxide: new clinical experience with an old medication in hematologic malignancies.

  2005cited by this paper
• Myelodysplastic syndromes--coping with ineffective hematopoiesis.

  2005cited by this paper
• Imatinib mesylate can induce complete molecular remission in FIP1L1-PDGFR-a positive idiopathic hypereosinophilic syndrome.

  2004cited by this paper
• Comparative expressed sequence hybridization studies of high‐hyperdiploid childhood acute lymphoblastic leukemia

  2004cited by this paper
• Clinical resistance to imatinib: mechanisms and implications.

  2004cited by this paper
• Secondary cytogenetic aberrations in childhood Philadelphia chromosome positive acute lymphoblastic leukemia are nonrandom and may be associated with outcome

  2004cited by this paper
• Identification of preleukemic precursors of hyperdiploid acute lymphoblastic leukemia in cord blood

  2004cited by this paper
• Adult Burkitt leukemia and lymphoma.

  2004cited by this paper
• Identification of a novel fusion gene in a pre‐B acute lymphoblastic leukemia with t(1;19)(q23;p13)

  2004cited by this paper
• Focus on myeloproliferative diseases and myelodysplastic syndromes.

  2004cited by this paper
• Identification of human chromosomes by DNA-binding fluorescent agents

  2004cited by this paper
• Three distinct subgroups of hypodiploidy in acute lymphoblastic leukaemia

  2004cited by this paper
• Split-signal FISH for detection of chromosome aberrations in acute lymphoblastic leukemia

  2004cited by this paper
• A pediatric approach to the WHO classification of myelodysplastic and myeloproliferative diseases

  2003cited by this paper
• Reassessment of the prognostic significance of hypodiploidy in pediatric patients with acute lymphoblastic leukemia

  2003cited by this paper
• A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome.

  2003cited by this paper
• Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia.

  2003cited by this paper
• Amplification of AML1 on a duplicated chromosome 21 in acute lymphoblastic leukemia: a study of 20 cases

  2003cited by this paper
• Origins of chromosome translocations in childhood leukaemia

  2003cited by this paper
• Amplification of AML1 in acute lymphoblastic leukemia is associated with a poor outcome

  2003cited by this paper
• The myelodysplastic syndrome(s): a perspective and review highlighting current controversies.

  2003cited by this paper
• Chronic myeloid leukemia in chronic phase responding to imatinib: the occurrence of additional cytogenetic abnormalities predicts disease progression.

  2003cited by this paper
• Novel translocations that disrupt the platelet‐derived growth factor receptor β (PDGFRB) gene in BCR–ABL‐negative chronic myeloproliferative disorders

  2003cited by this paper
• Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series.

  2003cited by this paper
• Implications of somatic mutations in the AML1 gene in radiation-associated and therapy-related myelodysplastic syndrome/acute myeloid leukemia.

  2003cited by this paper
• Double jeopardy from a single translocation: deletions of the derivative chromosome 9 in chronic myeloid leukemia.

  2003cited by this paper
• Inhibition of FLT3 in MLL. Validation of a therapeutic target identified by gene expression based classification.

  2003cited by this paper
• Role of constitutively activated protein tyrosine kinases in malignant myeloproliferative disorders: an update

  2003cited by this paper
• Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapy.

  2003cited by this paper
• Donor Lymphocyte Infusions for Patients who Relapse After Allogeneic Stem Cell Transplantation for Chronic Myeloid Leukaemia

  2003cited by this paper
• Amplification of band q22 of chromosome 21, including AML1, in older children with acute lymphoblastic leukemia: an emerging molecular cytogenetic subgroup

  2003cited by this paper
• Narrowing and genomic annotation of the commonly deleted region of the 5q- syndrome.

  2002cited by this paper
• Outcome of treatment in childhood acute lymphoblastic leukaemia with rearrangements of the 11q23 chromosomal region.

  2002cited by this paper
• Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling.

  2002cited by this paper
• The World Health Organization (WHO) classification of the myeloid neoplasms.

  2002cited by this paper
• The 8p11 Myeloproliferative Syndrome: A Distinct Clinical Entity Caused by Constitutive Activation of FGFR1

  2002cited by this paper
• Site-specific translocation and evidence of postnatal origin of the t(1;19) E2A-PBX1 fusion in childhood acute lymphoblastic leukemia

  2002cited by this paper
• E.S. Jaffe, N.L. Harris, H. Stein, J.W. Vardiman (eds). World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues

  2002cited by this paper
• 11q23 balanced chromosome aberrations in treatment‐related myelodysplastic syndromes and acute leukemia: Report from an International Workshop †

  2002cited by this paper
• The t(8;22) in chronic myeloid leukemia fuses BCR to FGFR1: transforming activity and specific inhibition of FGFR1 fusion proteins.

  2001cited by this paper
• Chromosome and Molecular Abnormalities in Myelodysplastic Syndromes

  2001cited by this paper
• Molecular mechanisms of leukemogenesis mediated by MLL fusion proteins

  2001cited by this paper
• An Atlas on Chromosomes in Hematological Malignancies. Example: 11q23 and MLL partners

  2001cited by this paper
• Myelodysplastic syndrome in childhood: a retrospective study of 189 patients in Japan

  2001cited by this paper
• Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Southwest Oncology Group study.

  2001cited by this paper
• Primary chromosomal rearrangements of leukemia are frequently accompanied by extensive submicroscopic deletions and may lead to altered prognosis.

  2001cited by this paper
• Outcome of treatment in children with Philadelphia chromosome-positive acute lymphoblastic leukemia.

  2000cited by this paper
• Prognostic impact of trisomies of chromosomes 10, 17, and 5 among children with acute lymphoblastic leukemia and high hyperdiploidy (> 50 chromosomes).

  2000cited by this paper
• Chromosome 20 deletions in myeloid malignancies: reduction of the common deleted region, generation of a PAC/BAC contig and identification of candidate genes

  2000cited by this paper
• Genomic aberrations and survival in chronic lymphocytic leukemia.

  2000cited by this paper
• Hyperdiploid acute lymphoblastic leukemia with 51 to 65 chromosomes: a distinct biological entity with a marked propensity to undergo apoptosis.

  1999cited by this paper
• Management of acute myeloid leukemia in elderly patients.

  1999cited by this paper
• Identification of a novel molecular partner of the E2A gene in childhood leukemia

  1999cited by this paper
• The World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues. Report of the Clinical Advisory Committee meeting, Airlie House, Virginia, November, 1997.

  1999cited by this paper
• Cytogenetic abnormalities associated with the t(12;21): a collaborative study of 169 children with t(12;21)-positive acute lymphoblastic leukemia

  1999cited by this paper
• Protracted and variable latency of acute lymphoblastic leukemia after TEL-AML1 gene fusion in utero.

  1999cited by this paper
• A multimodal approach in the diagnosis of patients with hematopoietic disorders.

  1999cited by this paper
• Cross‐validation of prognostic scores in myelodysplastic syndromes on 386 patients from a single institution confirms importance of cytogenetics

  1999cited by this paper
• Comparison of cytogenetics, Southern blotting, and fluorescence in situ hybridization as methods for detecting MLL gene rearrangements in children with acute leukemia and with 11q23 abnormalities

  1999cited by this paper
• Chronic myeloid leukemia.

  1999cited by this paper
• Myelodysplastic syndrome, juvenile myelomonocytic leukemia, and acute myeloid leukemia associated with complete or partial monosomy 7

  1999cited by this paper
• Patients with t(8;21)(q22;q22) and acute myeloid leukemia have superior failure-free and overall survival when repetitive cycles of high-dose cytarabine are administered.

  1999cited by this paper
• Fluorescence in situ hybridization analysis of biomarkers in cancer.

  1999cited by this paper
• World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997.

  1999cited by this paper
• Trisomy 9 in a Patient with Secondary Acute Myelogenous Leukemia Detected by Fluorescent in situ Hybridization

  1999cited by this paper
• Discordant detection of monosomy 7 by GTG-banding and FISH in a patient with Shwachman-Diamond syndrome without evidence of myelodysplastic syndrome or acute myelogenous leukemia.

  1999cited by this paper
• Myelodysplastic and myeloproliferative disorders of childhood: a study of 167 patients.

  1999cited by this paper
• Fluorescence in situ hybridization analysis of single-cell trisomies for determination of clonality.

  1998cited by this paper
• Ten novel 11q23 chromosomal partner sites

  1998cited by this paper
• Fluorescent in situ Hybridization for Identifying Cytogenetic Abnormalities in Inadequate and Suboptimal Specimens

  1998cited by this paper
• A patient with myelodysplastic syndrome studied by GTG-banding and fluorescent in situ hybridization (FISH).

  1998cited by this paper
• The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties.

  1998cited by this paper
• Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype.

  1998cited by this paper
• The AD1 and AD2 Transactivation Domains of E2A Are Essential for the Antiapoptotic Activity of the Chimeric Oncoprotein E2A-HLF

  1998cited by this paper
• 5q-, twenty-five years later: a synopsis.

  1997cited by this paper

• No citing papers are available for this paper.